Treatment factors affecting breast cancer-related lymphedema after systemic chemotherapy and radiotherapy in stage II/III breast cancer patients.
Identifieur interne : 001295 ( PubMed/Corpus ); précédent : 001294; suivant : 001296Treatment factors affecting breast cancer-related lymphedema after systemic chemotherapy and radiotherapy in stage II/III breast cancer patients.
Auteurs : So-Youn Jung ; Kyung Hwan Shin ; Myungsoo Kim ; Seung Hyun Chung ; Seeyoun Lee ; Han-Sung Kang ; Eun Sook Lee ; Youngmee Kwon ; Keun Seok Lee ; In Hae Park ; Jungsil RoSource :
- Breast cancer research and treatment [ 1573-7217 ] ; 2014.
English descriptors
- KwdEn :
- Adult, Aged, Antineoplastic Agents (adverse effects), Axilla (surgery), Breast Neoplasms (pathology), Breast Neoplasms (therapy), Female, Humans, Lymph Node Excision (adverse effects), Lymphedema (epidemiology), Lymphedema (etiology), Mastectomy, Middle Aged, Neoplasm Staging, Proportional Hazards Models, Radiotherapy (adverse effects), Retrospective Studies, Risk Factors.
- MESH :
- chemical , adverse effects : Antineoplastic Agents.
- adverse effects : Lymph Node Excision, Radiotherapy.
- epidemiology : Lymphedema.
- etiology : Lymphedema.
- pathology : Breast Neoplasms.
- surgery : Axilla.
- therapy : Breast Neoplasms.
- Adult, Aged, Female, Humans, Mastectomy, Middle Aged, Neoplasm Staging, Proportional Hazards Models, Retrospective Studies, Risk Factors.
Abstract
We evaluated whether the sequence or regimen of systemic chemotherapy could be a risk factor for breast cancer-related lymphedema (LE). We retrospectively analyzed 848 patients with stage II/III breast cancer who underwent curative surgery with adequate systemic therapy from 2004 to 2009. Adjuvant chemotherapy (ACT) was performed in 552 patients (65.1 %) and neoadjuvant chemotherapy (NAC) in 296 (34.9 %). We evaluated the incidence of LE based on clinicopathological factors and treatments. At a median follow-up of 5.1 years, 358 patients (42.2 %) had experienced LE and 243 (28.7 %) had retained (persistent LE) [120/552 (21.7 %) with ACT vs. 123/296 (41.6 %) with NAC; P < 0.001]. The incidence of LE in patients with taxane was greater than in those without taxane [233/704 (33.1 %) vs. 10/144 (6.9 %); P < 0.001]. Multivariate analysis showed that NAC [hazard ratio (HR), 1.63 in LE event; P < 0.001; HR, 1.39 in persistent LE; P = 0.02] and RT including supraclavicular area (SCRT) (HR 1.55; P = 0.02; HR 1.93; P = 0.006), number of dissected axillary lymph nodes (N-ALNs) >10 (HR, 1.37; P = 0.01; HR, 1.71; P = 0.001), advanced stage (HR, 1.31; P = 0.03; HR, 1.60; P = 0.002), and taxane (HR, 1.69; P = 0.03; HR, 2.07; P = 0.04) were independent risk factors for the LE occurrence. In addition to advanced stage, N-ALNs and SCRT, NAC, and taxane were shown to increase the risk of LE, which could help clinicians identify patients at risk for LE.
DOI: 10.1007/s10549-014-3137-x
PubMed: 25253173
Links to Exploration step
pubmed:25253173Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment factors affecting breast cancer-related lymphedema after systemic chemotherapy and radiotherapy in stage II/III breast cancer patients.</title><author><name sortKey="Jung, So Youn" sort="Jung, So Youn" uniqKey="Jung S" first="So-Youn" last="Jung">So-Youn Jung</name><affiliation><nlm:affiliation>Center for Breast Cancer, National Cancer Center, 111 Jungbalsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, 410-769, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Shin, Kyung Hwan" sort="Shin, Kyung Hwan" uniqKey="Shin K" first="Kyung Hwan" last="Shin">Kyung Hwan Shin</name></author><author><name sortKey="Kim, Myungsoo" sort="Kim, Myungsoo" uniqKey="Kim M" first="Myungsoo" last="Kim">Myungsoo Kim</name></author><author><name sortKey="Chung, Seung Hyun" sort="Chung, Seung Hyun" uniqKey="Chung S" first="Seung Hyun" last="Chung">Seung Hyun Chung</name></author><author><name sortKey="Lee, Seeyoun" sort="Lee, Seeyoun" uniqKey="Lee S" first="Seeyoun" last="Lee">Seeyoun Lee</name></author><author><name sortKey="Kang, Han Sung" sort="Kang, Han Sung" uniqKey="Kang H" first="Han-Sung" last="Kang">Han-Sung Kang</name></author><author><name sortKey="Lee, Eun Sook" sort="Lee, Eun Sook" uniqKey="Lee E" first="Eun Sook" last="Lee">Eun Sook Lee</name></author><author><name sortKey="Kwon, Youngmee" sort="Kwon, Youngmee" uniqKey="Kwon Y" first="Youngmee" last="Kwon">Youngmee Kwon</name></author><author><name sortKey="Lee, Keun Seok" sort="Lee, Keun Seok" uniqKey="Lee K" first="Keun Seok" last="Lee">Keun Seok Lee</name></author><author><name sortKey="Park, In Hae" sort="Park, In Hae" uniqKey="Park I" first="In Hae" last="Park">In Hae Park</name></author><author><name sortKey="Ro, Jungsil" sort="Ro, Jungsil" uniqKey="Ro J" first="Jungsil" last="Ro">Jungsil Ro</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25253173</idno><idno type="pmid">25253173</idno><idno type="doi">10.1007/s10549-014-3137-x</idno><idno type="wicri:Area/PubMed/Corpus">001295</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001295</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Treatment factors affecting breast cancer-related lymphedema after systemic chemotherapy and radiotherapy in stage II/III breast cancer patients.</title><author><name sortKey="Jung, So Youn" sort="Jung, So Youn" uniqKey="Jung S" first="So-Youn" last="Jung">So-Youn Jung</name><affiliation><nlm:affiliation>Center for Breast Cancer, National Cancer Center, 111 Jungbalsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, 410-769, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Shin, Kyung Hwan" sort="Shin, Kyung Hwan" uniqKey="Shin K" first="Kyung Hwan" last="Shin">Kyung Hwan Shin</name></author><author><name sortKey="Kim, Myungsoo" sort="Kim, Myungsoo" uniqKey="Kim M" first="Myungsoo" last="Kim">Myungsoo Kim</name></author><author><name sortKey="Chung, Seung Hyun" sort="Chung, Seung Hyun" uniqKey="Chung S" first="Seung Hyun" last="Chung">Seung Hyun Chung</name></author><author><name sortKey="Lee, Seeyoun" sort="Lee, Seeyoun" uniqKey="Lee S" first="Seeyoun" last="Lee">Seeyoun Lee</name></author><author><name sortKey="Kang, Han Sung" sort="Kang, Han Sung" uniqKey="Kang H" first="Han-Sung" last="Kang">Han-Sung Kang</name></author><author><name sortKey="Lee, Eun Sook" sort="Lee, Eun Sook" uniqKey="Lee E" first="Eun Sook" last="Lee">Eun Sook Lee</name></author><author><name sortKey="Kwon, Youngmee" sort="Kwon, Youngmee" uniqKey="Kwon Y" first="Youngmee" last="Kwon">Youngmee Kwon</name></author><author><name sortKey="Lee, Keun Seok" sort="Lee, Keun Seok" uniqKey="Lee K" first="Keun Seok" last="Lee">Keun Seok Lee</name></author><author><name sortKey="Park, In Hae" sort="Park, In Hae" uniqKey="Park I" first="In Hae" last="Park">In Hae Park</name></author><author><name sortKey="Ro, Jungsil" sort="Ro, Jungsil" uniqKey="Ro J" first="Jungsil" last="Ro">Jungsil Ro</name></author></analytic><series><title level="j">Breast cancer research and treatment</title><idno type="eISSN">1573-7217</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antineoplastic Agents (adverse effects)</term><term>Axilla (surgery)</term><term>Breast Neoplasms (pathology)</term><term>Breast Neoplasms (therapy)</term><term>Female</term><term>Humans</term><term>Lymph Node Excision (adverse effects)</term><term>Lymphedema (epidemiology)</term><term>Lymphedema (etiology)</term><term>Mastectomy</term><term>Middle Aged</term><term>Neoplasm Staging</term><term>Proportional Hazards Models</term><term>Radiotherapy (adverse effects)</term><term>Retrospective Studies</term><term>Risk Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Agents</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Lymph Node Excision</term><term>Radiotherapy</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Lymphedema</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Lymphedema</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Axilla</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Humans</term><term>Mastectomy</term><term>Middle Aged</term><term>Neoplasm Staging</term><term>Proportional Hazards Models</term><term>Retrospective Studies</term><term>Risk Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We evaluated whether the sequence or regimen of systemic chemotherapy could be a risk factor for breast cancer-related lymphedema (LE). We retrospectively analyzed 848 patients with stage II/III breast cancer who underwent curative surgery with adequate systemic therapy from 2004 to 2009. Adjuvant chemotherapy (ACT) was performed in 552 patients (65.1 %) and neoadjuvant chemotherapy (NAC) in 296 (34.9 %). We evaluated the incidence of LE based on clinicopathological factors and treatments. At a median follow-up of 5.1 years, 358 patients (42.2 %) had experienced LE and 243 (28.7 %) had retained (persistent LE) [120/552 (21.7 %) with ACT vs. 123/296 (41.6 %) with NAC; P < 0.001]. The incidence of LE in patients with taxane was greater than in those without taxane [233/704 (33.1 %) vs. 10/144 (6.9 %); P < 0.001]. Multivariate analysis showed that NAC [hazard ratio (HR), 1.63 in LE event; P < 0.001; HR, 1.39 in persistent LE; P = 0.02] and RT including supraclavicular area (SCRT) (HR 1.55; P = 0.02; HR 1.93; P = 0.006), number of dissected axillary lymph nodes (N-ALNs) >10 (HR, 1.37; P = 0.01; HR, 1.71; P = 0.001), advanced stage (HR, 1.31; P = 0.03; HR, 1.60; P = 0.002), and taxane (HR, 1.69; P = 0.03; HR, 2.07; P = 0.04) were independent risk factors for the LE occurrence. In addition to advanced stage, N-ALNs and SCRT, NAC, and taxane were shown to increase the risk of LE, which could help clinicians identify patients at risk for LE.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25253173</PMID><DateCreated><Year>2014</Year><Month>10</Month><Day>14</Day></DateCreated><DateCompleted><Year>2015</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2014</Year><Month>10</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-7217</ISSN><JournalIssue CitedMedium="Internet"><Volume>148</Volume><Issue>1</Issue><PubDate><Year>2014</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Breast cancer research and treatment</Title><ISOAbbreviation>Breast Cancer Res. Treat.</ISOAbbreviation></Journal><ArticleTitle>Treatment factors affecting breast cancer-related lymphedema after systemic chemotherapy and radiotherapy in stage II/III breast cancer patients.</ArticleTitle><Pagination><MedlinePgn>91-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10549-014-3137-x</ELocationID><Abstract><AbstractText>We evaluated whether the sequence or regimen of systemic chemotherapy could be a risk factor for breast cancer-related lymphedema (LE). We retrospectively analyzed 848 patients with stage II/III breast cancer who underwent curative surgery with adequate systemic therapy from 2004 to 2009. Adjuvant chemotherapy (ACT) was performed in 552 patients (65.1 %) and neoadjuvant chemotherapy (NAC) in 296 (34.9 %). We evaluated the incidence of LE based on clinicopathological factors and treatments. At a median follow-up of 5.1 years, 358 patients (42.2 %) had experienced LE and 243 (28.7 %) had retained (persistent LE) [120/552 (21.7 %) with ACT vs. 123/296 (41.6 %) with NAC; P < 0.001]. The incidence of LE in patients with taxane was greater than in those without taxane [233/704 (33.1 %) vs. 10/144 (6.9 %); P < 0.001]. Multivariate analysis showed that NAC [hazard ratio (HR), 1.63 in LE event; P < 0.001; HR, 1.39 in persistent LE; P = 0.02] and RT including supraclavicular area (SCRT) (HR 1.55; P = 0.02; HR 1.93; P = 0.006), number of dissected axillary lymph nodes (N-ALNs) >10 (HR, 1.37; P = 0.01; HR, 1.71; P = 0.001), advanced stage (HR, 1.31; P = 0.03; HR, 1.60; P = 0.002), and taxane (HR, 1.69; P = 0.03; HR, 2.07; P = 0.04) were independent risk factors for the LE occurrence. In addition to advanced stage, N-ALNs and SCRT, NAC, and taxane were shown to increase the risk of LE, which could help clinicians identify patients at risk for LE.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>So-Youn</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Center for Breast Cancer, National Cancer Center, 111 Jungbalsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, 410-769, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Kyung Hwan</ForeName><Initials>KH</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Myungsoo</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Seung Hyun</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Seeyoun</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Han-Sung</ForeName><Initials>HS</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Eun Sook</ForeName><Initials>ES</Initials></Author><Author ValidYN="Y"><LastName>Kwon</LastName><ForeName>Youngmee</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Keun Seok</ForeName><Initials>KS</Initials></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>In Hae</ForeName><Initials>IH</Initials></Author><Author ValidYN="Y"><LastName>Ro</LastName><ForeName>Jungsil</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Breast Cancer Res Treat</MedlineTA><NlmUniqueID>8111104</NlmUniqueID><ISSNLinking>0167-6806</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001365" MajorTopicYN="N">Axilla</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008197" MajorTopicYN="N">Lymph Node Excision</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008408" MajorTopicYN="N">Mastectomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011878" MajorTopicYN="N">Radiotherapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>08</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>09</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25253173</ArticleId><ArticleId IdType="doi">10.1007/s10549-014-3137-x</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001295 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001295 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:25253173
|texte= Treatment factors affecting breast cancer-related lymphedema after systemic chemotherapy and radiotherapy in stage II/III breast cancer patients.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:25253173" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |